Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,466.8
-18.9 (-0.76%)

 

  • STI Straits Times Index
    2,466.8
    -18.9 (-0.76%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,506.4
    7.0 (0.46%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,835.3
    -115.3 (-0.48%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,304.5
    -12.5 (-0.38%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,360.3
    40.9 (0.18%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    4,956.0
    -43.4 (-0.87%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 483.0M
  • Value: 605.4M
  • Rise: 110
  • Fall: 131
  • Unch: 542

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.147-0.004
Alset0.065+0.001
Singtel2.180-0.030
Medtecs Intl1.110+0.100
Vicplas Intl0.350+0.040
Golden Agri-Res0.142-
ThaiBev0.595-
Lippo Malls Tr0.101-0.006
Rex Intl0.142+0.001
SPH1.030-0.040

World Indices

World Indices
Name Last Change
Nasdaq 10,778.8 -14.5
HSI 23,806.4 -144.3
HSCEI 9,618.1 -22.3
Jakarta 4,956.0 -43.4
Nikkei 225 23,360.3 +40.9
SSE Comp 3,298.6 -18.4
Shanghai A 3,457.1 -19.2
Shanghai B 249.9 -1.4
KOSPI 2,333.7 -55.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

IX Biopharma IX BIOPHARMA LTD.
Quotes 10 Minutes Delayed. Updated at 22 Sep 2020 13:44
Last (SGD): 0.220 Change: - High: 0.225 Remarks: -
Change (%): - Low: 0.215
Open 0.220 Yesterday's Close 0.220
Buy Price 0.220 Sell Price 0.225
Buy Volume ('000) 37.1 Sell Volume ('000) 699.6
Cumulative Volume ('000) 1,079.3 Cumulative Value 237,596
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.01514 Trailing EPS (SGD) e -0.01514 NAV (SGD) b 0.0294
PE a - Trailing PE f - Price / NAV b 7.4830
Dividend (SGD) d - Cash In Hand (SGD) g 0.0064 Issued & Paid-up Shares c 693,386,000
Dividend Yield (%) d - Price / Cash In Hand g 34.375 Treasury Shares h -
Beta - 75 Daysi 0.781 R-Squared - 75 Days(%)i 1.89 Market Cap (M) 152.545
Beta - 500 Daysi 0.552 R-Squared - 500 Days (%)i 1.52 Enterprise Value (M) 150.800
Piotroski F Score 1 Exchange Code 42C Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 72.8147 6-Month VWAP 0.285 Free Float (%) 43.8
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Prof, Scientific & Technical Activities - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 11 Sep 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference IX Biopharma SGX 152.545 - - 7.4830 -
Industry Medical & Biotechnology SGX 925.186 21.860 21.100 1.3170 2.078
Pharmaceuticals: Major SGX 92.090 2431.015 115.115 4.1261 1.087
Local Peer Hyphens Pharma SGX 114.163 17.479 14.735 2.5216 2.632
Local Peer Pharmesis Intl SGX 6.095 - - 0.5290 -
Global Peer JOHNSON & JOHNSON NYSE 382,022.182 25.268 25.158 6.0660 2.584
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 220,801.870 31.327 30.590 4.1032 2.059
Global Peer MERCK & CO INC NYSE 210,255.721 21.361 20.064 7.6064 2.729
Global Peer PFIZER INC NYSE 200,158.818 12.301 14.126 3.1112 4.037
Global Peer ABBVIE INC NYSE 157,228.705 20.050 22.780 10.6901 4.129
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 146,740.268 109.464 68.165 11.9914 2.450
Global Peer ELI LILLY AND COMPANY NYSE 144,599.135 31.178 25.738 35.3290 1.708
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 130,209.536 37.863 - 2.6523 2.875
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 128,033.689 39.351 10.424 1.8008 2.299
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 125,048.514 21.416 20.388 13.8179 1.648
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), ROYALTY PHARMA PLC (NASDAQ), INNOVENT BIO (HKEx), CUREVAC NV (NASDAQ), REPLIGEN CORP (NASDAQ), SINOPHARM (HKEx), CANSINOBIO-B (HKEx), JUNSHI BIO (HKEx), SH PHARMA (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HYGEIA HEALTH (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), TURNING POINT THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), HENLIUS-B (HKEx), CHINARES PHARMA (HKEx), PRINCIPIA BIOPHARMA INC (NASDAQ), ADC THERAPEUTICS SA (NYSE), CHINAGRANDPHARM (HKEx), AKESO-B (HKEx), CMS (HKEx), HEPALINK (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), TRAD CHI MED (HKEx), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), OCUMENSION-B (HKEx), UNITED LAB (HKEx), INNOCARE-B (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), SSY GROUP (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), GENERATION BIO CO (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), NURIX THERAPEUTICS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), REPARE THERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), Kimia Farma Tbk. (IDX), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), CKLIFE SCIENCES (HKEx), CSTONE PHARMA-B (HKEx), PHATHOM PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TONGRENTANGCM (HKEx), KRYSTAL BIOTECH INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), PETIQ INC (NASDAQ), ANNEXON INC (NASDAQ), PROVENTION BIO INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), IMMUNOTECH-B (HKEx), TCR2 THERAPEUTICS INC (NASDAQ), AC IMMUNE SA (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), HUA MEDICINE-B (HKEx), APREA THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), TRICIDA INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), IGBB (Bursa), KALA PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), SHINEWAY PHARM (HKEx), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), STARPHARMA HOLDINGS LIMITED (ASX), BEYONDSPRING INC (NASDAQ), IMARA INC (NASDAQ), 89BIO INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), IMMUNIC INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), DURECT CORP (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), PYC THERAPEUTICS LIMITED (ASX), AMAG PHARMACEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), BSTEAD (Bursa), UROVANT SCIENCES LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), TOT BIOPHARM-B (HKEx), XERIS PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), CYCLERION THERAPEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), VERRICA PHARMACEUTICALS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), MUSTANG BIO INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), ESSA PHARMA INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), VERU INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), ETON PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), RECCE PHARMACEUTICALS LTD (ASX), SOL GEL TECHNOLOGIES LTD (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), CH BIOTECH SER (HKEx), HARROW HEALTH INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), BIOMX INC (NYSE American), EVOLUS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), KOTRA (Bursa), PROTARA THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), MEDIWOUND LTD (NASDAQ), Merck Tbk. (IDX), NEW RAY MEDIC (HKEx), Phapros Tbk. (IDX), EYENOVIA INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), IP (SET), NEP INTERLONG (HKEx), ASSERTIO HOLDINGS INC (NASDAQ), PAK FAH YEOW (HKEx), EYEPOINT PHARMACEUTICALS INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 10 ORD SHS (R/S) (NASDAQ), NOVAN INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), RACE ONCOLOGY LTD (ASX), NOVA (Bursa), PALLA PHARMA LTD (ASX), BIOHLDG (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), CHARMACY PHAR (HKEx), BAUDAX BIO INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), NC HEALTHCARE (HKEx), NOXOPHARM LTD (ASX), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), PAINREFORM LTD (NASDAQ), WAI YUEN TONG (HKEx), IMMURON LIMITED (ASX), PROPHASE LABS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TBG DIAGNOSTICS LTD (ASX), ONCTERNAL THERAPEUTICS INC (NASDAQ), INVION LTD (ASX), PURAPHARM (HKEx), ANNOVIS BIO INC (NYSE American), MANNATECH INC (NASDAQ), SANAI HEALTH GP (HKEx), MEDLAB CLINICAL LIMITED (ASX), AGEX THERAPEUTICS INC (NYSE American), EXTRAWELL PHAR (HKEx), JCT (SET), DARE BIOSCIENCE INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), SUN BIOPHARMA INC (NASDAQ), EXOPHARM LTD (ASX), SPRING BANK PHARMACEUTICALS INC (NASDAQ), PHARMAXIS (ASX), BRICKELL BIOTECH INC (NASDAQ), ENTERA BIO LTD (NASDAQ), SUNZEN (Bursa), ACRUX (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), FIJI KAVA LTD (ASX), ADIAL PHARMACEUTICALS INC (NASDAQ), SINOLIFE UTD (HKEx), NOVUS THERAPEUTICS INC (NASDAQ), PASHUN INT'L (HKEx), CHINA SXT PHARMACEUTICALS INC (NASDAQ), TALI DIGITAL LIMITED (ASX), TIMBER PHARMACEUTICALS INC (NYSE American), SUDA PHARMACEUTICALS LTD (ASX), CRESO PHARMA LTD (ASX), CELLMID LIMITED (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), FARMAFORCE LTD (ASX), TELIGENT INC NEW (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days --0.040
-15.38 %
20 Days --0.085
-27.87 %
Medium Term Return 3 Months --0.025
-10.20 %
6 Months -+0.075
+51.72 %
1 Year -+0.020
+10.00 %
Long Term Return 2 Years -+0.050
+29.41 %
3 Years --0.010
-4.35 %
5 Years --0.076
-25.68 %
Annualised Return Annualised --
-5.76 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.130 - 0.350 Change From 1 Year Low +0.090 % Change From 1 Year Low (%) +69.23
Change From 1 Year High -0.130 % Change From 1 Year High (%) -37.14
2 Years Range 0.130 - 0.350 Change From 2 Years Low +0.090 % Change From 2 Years Low (%) +69.23
Change From 2 Years High -0.130 % Change From 2 Years High (%) -37.14
5 Years Range 0.130 - 0.483 Change From 5 Years Low +0.090 % Change From 5 Years Low (%) +69.23
Change From 5 Years High -0.263 % Change From 5 Years High (%) -54.48
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Company was incorporated in Singapore on 8 May 2004 as a private company limited under the name of Ixblue International Pte. Ltd. On 22 January 2008, the name of its Company was changed to iX Biopharma Pte Ltd. The Company was converted into a public limited company and the name of its Company was changed to iX Biopharma Ltd on 31 January 2013.iX Biopharma Ltd. focuses on the development and commercialisation of innovative therapies for pain management and male erectile dysfunction. The Company leverages its patented sublingual drug delivery technology, WaferiXTM, to develop proprietary products that incorporate FDA-approved pharmacologically active compounds. The Group currently have three drugs under development - Wafermine™, Wafernyl™ and PheoniX™.The Group operates an integrated business model encompassing drug development, manufacturing and supply. Its manufacturing facility in Australia is TGA-approved and GMP-compliant, and supplies drugs to hospitals under Schedule 5A of the TGR.

IPO Performance

Listing Date 22 Jul 2015 Full Subscription Rate (x) 1.36
No of Placement Shares (M) 64.50 No of Public Offer Shares (M) 1.00 Public Offer Subscription Rate (x) 24.65
IPO Price (SGD) a 0.454 First Day Close (SGD) a 0.552 First Week Close (SGD) a 0.414
Current vs IPO Price (%) -51.54 First Day Gain (%) +21.59 First Week Gain (%) -8.81
Notes:
  1. Adjusted for the following: Rights Issue 1 for 25 @ $0.21 on 22/06/2016

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Jun 2019 Part 1(4.31 MB)
Annual Report 2018 Jun 2018 Part 1(6.28 MB)
Annual Report 2017 Jun 2017 Part 1(1.40 MB)
Annual Report 2016 Jun 2016 Part 1(4.32 MB)
Part 2(0.12 MB)
Annual Report 2015 Jun 2015 Part 1(0.59 MB)
IPO Prospectus
IPO Prospectus 2015 Jul 2015 Part 1(3.65 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
21 Sep 2020 0.235 0.235 0.220 0.220 6,923,900 0.2309
18 Sep 2020 0.220 0.225 0.220 0.220 3,890,100 0.2217
17 Sep 2020 0.215 0.225 0.215 0.220 3,644,800 0.2224
16 Sep 2020 0.215 0.225 0.215 0.215 2,570,600 0.2192
15 Sep 2020 0.220 0.230 0.215 0.215 7,382,600 0.2235
14 Sep 2020 0.235 0.235 0.220 0.220 5,526,400 0.2263
11 Sep 2020 0.230 0.240 0.225 0.235 7,504,800 0.2327
10 Sep 2020 0.255 0.260 0.225 0.230 7,654,500 0.2399
09 Sep 2020 0.260 0.260 0.255 0.255 5,635,100 0.2562
08 Sep 2020 0.260 0.270 0.255 0.260 16,267,700 0.2628
07 Sep 2020 0.270 0.270 0.260 0.260 1,347,300 0.2643
04 Sep 2020 0.255 0.275 0.255 0.265 5,561,000 0.2644
03 Sep 2020 0.260 0.275 0.255 0.265 6,455,900 0.2637
02 Sep 2020 0.265 0.265 0.260 0.260 2,366,900 0.2629
01 Sep 2020 0.265 0.270 0.265 0.265 2,891,000 0.2654
31 Aug 2020 0.270 0.275 0.260 0.265 7,497,100 0.2665
28 Aug 2020 0.275 0.285 0.275 0.275 4,740,800 0.2774
27 Aug 2020 0.290 0.290 0.275 0.275 7,975,800 0.2818
26 Aug 2020 0.295 0.295 0.290 0.290 1,819,800 0.2900
25 Aug 2020 0.305 0.305 0.285 0.290 3,402,200 0.2937
24 Aug 2020 0.305 0.315 0.300 0.305 8,992,500 0.3070
21 Aug 2020 0.275 0.315 0.270 0.305 18,715,600 0.2955
Summary
Current 2 Weeks
(08 Sep 2020 to 21 Sep 2020)
0.260 0.270 0.215 0.220 67,000,500 -
Previous 2 Weeks
(25 Aug 2020 to 07 Sep 2020)
0.305 0.305 0.215 0.260 44,057,800 -
4 Weeks from
(24 Jul 2020 to 24 Aug 2020)
0.330 0.340 0.215 0.305 164,243,100 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.